Trial expands the eligible patient population and overall NeuVax clinical trial portfolio Recent patent allowance provides intellectual property protection for NeuVax in combination with Herceptin in any HER2/neu expressing cancer
PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients investment picks
Inc. (NYSE: DWRE), the industry-leading provider of enterprise cloud
commerce solutions, today announced that the company will present at the
UBS Global Technology Conference
Tim Adams, Demandware Chief Financial Officer, will present on
Thursday, November 20 th at 8:30 a.m. PST at Cavallo Point,
The Lodge at the Golden Gate
An audio webcast of the presentation will be available on Demandware’s
investor relations website at http://investors.demandware.com .
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will
present a corporate overview at the Stifel 2014 Healthcare Conference,
November 18, 2014 at 1:50 p.m. EST at The New York Palace Hotel in New
AES Eletropaulo markedly reduces call volume and lowers processing time for a fast ROI RA'ANANA, Israel , November 11, 2014 /PRNewswire/ --
NICE Systems (NASDAQ: NICE) today announced that AES Eletropaulo, a major power distributor in Brazil , has deployed NICE Real-Time Process Optimization in its contact center to improve operational efficiency, lower the number of repeat calls, and reduce average processing time.
MEF GEN14 — Transition
Networks , Inc., the fiber access technology expert, a wholly owned
subsidiary of Communications
Systems, Inc. (NASDAQ-GM: JCS), announced that it will be actively
participating in the MEF GEN14 event being held November 17-20 in
MEF GEN14 is a global Ethernet networking event for industry
professionals involved in all aspects of state-of-the-art innovations
powered by Carrier Ethernet, SDN, NFV and optical networking.
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company
focused on the discovery and development of G protein coupled receptor
(GPCR) biased ligands, today announced financial results for the quarter
ended September 30, 2014 and provided an update regarding its ongoing
Integration of Samsung's mobile innovations with the SAP Mobile Platform will help unlock new possibilities for developers and enterprise customers across key industries
SEOUL, South Korea , and BERLIN , Nov.
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave
Stack, president, chief executive officer and chairman of Pacira
Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global
London Healthcare Conference at 10:40 a.m. GMT (5:40 a.m. ET) on
By Barbara Kollmeyer, MarketWatch Strategist: S&P 500 could be a sell at 2,078
MADRID (MarketWatch) -- U.S. stock futures nudged higher on Tuesday, as investors waited to see if Wall Street's record run will continue, though a Veterans Day holiday could mean thinner volume.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.